Authorizes and supports use, distribution, training, research, and regulatory guidance for drug‑checking supplies (for example, fentanyl and xylazine test strips) to help prevent overdoses, provided possession and purchase comply with Federal and State law. Requires HHS, working with NIH, ONDCP, FDA, and DEA, to publish research and marketing frameworks for test strip technologies and to study the public‑health effects of improved availability and use of drug‑checking supplies, with a report to Congress within two years.